1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

European Nanomaterial Definition Brings Measurement Challenges

 
• By Ryan Nelson

The European Commission’s definition of “nanomaterial,” to potentially be used in legislation, appears to be relatively simple. In practice, measuring particles against the standard offers a number of technological challenges.

Companies subject to nanotechnology requirements under European law could face the challenge of measuring materials against the European Commission’s recommended definition, which isn’t as simple as it may seem, a September report from the EC’s Joint Research Centre suggests.

In late 2011, the European Union’s regulatory body adopted a definition for what constitutes a “nanomaterial” from a regulatory standpoint....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Merck, AstraZeneca Downplay Impact of European Tariffs Despite Timing Uncertainties

 
• By Cathy Kelly

Meanwhile, companies continue discussions with the Trump Administration over ways of increasing what European nations pay for drugs as an alternative to imposing a Most Favored Nation drug pricing policy in the US.

EU 15% Tariff Deal Still Leaves Questions For Pharma On Possible Grace Period, Generic Exemption

 
• By Jessica Merrill

While the 15% rate is a substantial blow for pharmaceutical firms, the US-EU deal provides a framework for trade agreements with other countries that could see the industry avoiding higher tariffs elsewhere.

Medicare Part B ASP Proposal Sets ‘Guardrails’ Around Bona Fide Service Fee Reporting

 
• By Cathy Kelly

Average sales prices, and Medicare spending on some drugs, would be expected to be lower, CMS says in the Physician Fee Schedule proposed rule.

A Record Year For US FDA Approvals? Commissioner Says It’s Possible

 
• By Michael McCaughan

FDA Commissioner Martin Makary suggested 60 new molecular entities could be approved in 2025, which appears possible, but can the strained staff deliver?

More from North America